FDA requires more CV data to approve Takeda's diabetes drug alogliptin
This article was originally published in Scrip
Executive Summary
The US FDA has informed Takeda that it requires more clinical data to rule out any cardiovascular risks before it can complete the review of the NDA for its type 2 diabetes DPP-4 inhibitor, alogliptin.